A5092247336- Endometrial and Cervical Cancer Treatments
- Ovarian cancer diagnosis and treatment
- Cancer Immunotherapy and Biomarkers
- Endometriosis Research and Treatment
- DNA Repair Mechanisms
- Management of metastatic bone disease
- Intraperitoneal and Appendiceal Malignancies
- Uterine Myomas and Treatments
- PARP inhibition in cancer therapy
- Cancer, Stress, Anesthesia, and Immune Response
- Immune cells in cancer
Regional Cancer Center
2023-2024
Irkutsk Regional Clinical Hospital
2024
State Healthcare Institution "Regional Clinical Oncological Dispensary"
2024
Only one-third of patients with advanced MSS/pMMR endometrial cancer exhibit a lasting response to the combination treatment Pembrolizumab and Lenvatinib. The combined administration these two drugs is based on Lenvatinib’s ability modulate tumor microenvironment, enabling exert its effect. These findings underscore importance exploring microenvironment parameters identify markers that can accurately select candidates for this type therapy. An open non-randomized observational association...
Homologous recombination repair deficiency (HRD) is involved in the development of high-grade serous ovarian carcinoma (HGSOC) and its elevated sensitivity to platinum-based chemotherapy. To investigate heterogeneity HRD-positive HGSOC we evaluated HRD status, including BRCA mutations, genomic scar score, methylation status BRCA1/2 genes 352 specimens. We then divided cohort into three molecular subgroups, mutation (BRCA+), BRCA1 (Meth+), rest HRD+ (HRD+BRCA-Meth-), their first-line...
We present our experience in using cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer patients treated at Irkutsk Regional Cancer Center. All were divided into 2 groups. Group I consisted of 15 patients, who underwent only. II comprised 17 HIPEC. The main eligibility criteria this study verified peritoneal carcinomatosis resectable cancer. primary analysis these groups included: preoperative period, length operation, postoperative stay,...
Background. The inclusion of lenvatinib in the immunotherapy regimen for patients with MSS/pMMR endometrial cancer (EC) is due to its ability modulate tumor microenvironment, which allows use pembrolizumab low-immunogenic tumors. However, only 30 % advanced or metastatic EC have a clinical response when treated and lenvatinib. In this regard, there an obvious need identify biomarkers that allow accurate selection candidates type therapy. Aim. To determine predictive value subpopulations...
Aim. To assess the efficacy and safety of lenvatinib plus pembrolizumab for treatment mismatch repair-proficient (pMMR) endometrial cancer (EC) in routine clinical practice Russia. Materials methods. This multicenter, retrospective, cohort study included 114 patients with recurrent metastatic EC from 37 centers Russia treated between December 2020 November 2024. Patients histologically verified without microsatellite instability were included. The primary endpoint was progression-free...
Background . Endometrial cancer (EC) is one of the most significant oncogynecological problems. The main mortality cause in this disease, as case other malignant neoplasms, tumor progression. presence mutations associated with mismatch repair-deficient great prognostic importance. Immunotargeting therapy (ITT), lenvatinib combination pembrolizumab, seems to be effective solution second line treatment advanced EC without microsatellite instability. At same time, group such patients...